• LAST PRICE
    9.2699
  • TODAY'S CHANGE (%)
    Trending Down-0.0501 (-0.5376%)
  • Bid / Lots
    9.2600/ 4
  • Ask / Lots
    9.2700/ 2
  • Open / Previous Close
    9.2500 / 9.3200
  • Day Range
    Low 9.2100
    High 9.3200
  • 52 Week Range
    Low 9.0500
    High 23.2200
  • Volume
    130,672
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 9.32
TimeVolumeINDV
09:32 ET47389.27
09:34 ET3009.25
09:36 ET42059.245
09:38 ET30649.24
09:39 ET2709.26
09:43 ET68719.23
09:48 ET48769.245
09:50 ET30889.24
09:52 ET38619.25
09:54 ET39329.245
09:56 ET44619.27
09:57 ET63009.28
09:59 ET3009.295
10:01 ET36459.28
10:03 ET1009.29
10:06 ET69259.29
10:08 ET24039.285
10:10 ET4199.29
10:12 ET4949.31
10:14 ET9009.3
10:15 ET10799.27
10:19 ET1009.27
10:21 ET41539.25
10:24 ET43379.28
10:26 ET8769.283
10:30 ET26879.28
10:32 ET9769.28
10:39 ET37149.273
10:42 ET6789.29
10:44 ET5009.29
10:46 ET19959.28
10:48 ET3969.283
10:50 ET9039.28
10:53 ET5009.28
10:55 ET12449.3
10:57 ET91749.25
11:00 ET2629.25
11:02 ET34739.27
11:04 ET1009.27
11:06 ET5009.28
11:08 ET4009.27
11:09 ET5089.2699
Data delayed at least 15 minutes.

Company Information

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

Contact Information

Headquarters
10710 Midlothian Turnpike Suite 125, North ChesterfieldCHESTERFIELD, VA, United States 23235
Phone
804-379-1090
Fax
---

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$889.9M
Revenue (TTM)
$855.2M
Shares Outstanding
129.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.10
EPS
$-0.81
Book Value
$0.00
P/E Ratio
0.0x
Price/Sales (TTM)
1.0
Price/Cash Flow (TTM)
---
Operating Margin
-16.48%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.